title: Treatment of hemolysis with intravenous unfractionated heparin using an antifactor Xa-based monitoring protocol.
authors.affiliation: Cardiology Division, Department of Medicine, University of Minnesota, Minneapolis, Minn.
authors.forename: Sirtaz
authors.initials: S
authors.lastname: Adatya
authors.affiliation: Cardiology Division, Department of Medicine, University of Minnesota, Minneapolis, Minn.
authors.forename: Ranjit
authors.initials: R
authors.lastname: John
authors.affiliation: Cardiology Division, Department of Medicine, University of Minnesota, Minneapolis, Minn.
authors.forename: Peter M
authors.initials: PM
authors.lastname: Eckman
mesh_terms: D061605:Administration, Intravenous; D000368:Aged; D015415:Biomarkers / Q000097:blood; D016903:Drug Monitoring / Q000379:methods*; D015951:Factor Xa / Q000378:metabolism*; D065427:Factor Xa Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D006353:Heart-Assist Devices / Q000009:adverse effects*; D006461:Hemolysis / Q000187:drug effects*; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D010314:Partial Thromboplastin Time; D011237:Predictive Value of Tests; D011474:Prosthesis Design; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left
chemical_list: D015415:Biomarkers; D065427:Factor Xa Inhibitors; D006493:Heparin; D015951:Factor Xa